New drug shows promise for painful hand and foot pustules
NCT ID NCT03135548
First seen Nov 01, 2025
Summary
This study tested a drug called spesolimab in 59 adults with palmoplantar pustulosis, a painful skin condition causing pustules on hands and feet. Participants received low or high doses of the drug or a placebo for 12 weeks. The main goal was to see if the drug safely reduced pustules and skin symptoms. Results suggest spesolimab may help control the disease, but larger studies are needed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PSORIASIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Aarhus University Hospital, Skejby
Aarhus, 8200, Denmark
-
Bispebjerg og Frederiksberg Hospital
København NV, 2400, Denmark
-
Charité - Universitätsmedizin Berlin
Berlin, 10117, Germany
-
Dr. Irina Turchin PC Inc.
Fredericton, New Brunswick, E3B 1G9, Canada
-
Gentofte Hospital
Hellerup, 2900, Denmark
-
Hospital Ramón y Cajal
Madrid, 28034, Spain
-
Hospital Santa Creu i Sant Pau
Barcelona, 08026, Spain
-
Hospital Universitario Infanta Leonor
Madrid, 28031, Spain
-
Innovaderm Research Inc.
Montreal, Quebec, H2K 4L5, Canada
-
Karolinska Univ. sjukhuset
Stockholm, 171 76, Sweden
-
Ospedale San Giovanni di Dio
Cagliari, 09124, Italy
-
Pol. Universitario Tor Vergata
Roma, 00133, Italy
-
Sahlgrenska US, Göteborg
Gothenburg, 413 45, Sweden
-
TFS Trial Form Support GmbH
Hamburg, 20537, Germany
-
Universitätsklinikum Frankfurt
Frankfurt am Main, 60596, Germany
-
Universitätsklinikum Heidelberg
Heidelberg, 69120, Germany
-
Universitätsklinikum Schleswig-Holstein, Campus Kiel
Kiel, 24105, Germany
-
York Dermatology Clinic and Research Centre
Richmond Hill, Ontario, L4C 9M7, Canada
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Spesolimab
What this could lead to
If successful, this could lead to a new treatment option for palmoplantar pustulosis, reducing painful pustules and improving quality of life.
What could go wrong
This is an early Phase 2 trial with only 59 participants, so results may not hold up in larger studies. The drug may cause side effects and is not a cure.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.